Alexandra Fulk
@Sands Capital Ventures, Llc
Latest period2024 - Q3ReportedManaged Assets$355.771MTotal holdings20
Assets growth rate19.16%Assets growth rate (2-Q avg)-4.41%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Sands Capital Ventures, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 20 positions.
Assets under management
The assets under management (AUM) of Sands Capital Ventures, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 355.771M in assets, with a quarterly growth rate of 19.16% and a 2-quarter average growth rate of -4.41%. The portfolio is managed by Alexandra Fulk, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
KVYOKlaviyo Inc
| 34.96% | $124.372M 3.515M shares@ $35.39 avg price | Decreased -0.02% |
NUNu Hldgs Ltd
| 21.1% | $75.059M 5.499M shares@ $13.65 avg price | Decreased -24.96% |
DASHDoordash Inc
| 16.99% | $60.423M 423,338 shares@ $142.74 avg price | Increased 0.06% |
BIOABioage Labs Inc
| 6.36% | $22.596M 1.086M shares@ $20.8 avg price | New Position |
ACRVAcrivon Therapeutics Inc
| 4.18% | $14.858M 2.123M shares@ $7.0 avg price | |
PATHUipath Inc
| 4.16% | $14.787M 1.155M shares@ $12.81 avg price | |
SNOWSnowflake Inc
| 3.5% | $12.44M 108,304 shares@ $114.86 avg price | |
TXG10x Genomics Inc
| 3.06% | $10.878M 481,770 shares@ $22.59 avg price | |
ABOSAcumen Pharmaceuticals Inc
| 2.39% | $8.474M 3.417M shares@ $2.48 avg price | |
TARSTarsus Pharmaceuticals Inc
| 1.58% | $5.591M 170,000 shares@ $32.89 avg price |